Namaxir (Methotrexate)

Methotrexate blocks the enzyme dihydrofolate reductase, disrupting folate metabolism and preventing the formation of nucleotides needed for DNA synthesis. This action limits the proliferation of immune cells involved in inflammation and of malignant cells that divide rapidly, providing therapeutic benefit in autoimmune diseases and cancers.

The specific dose of methotrexate is determined by the prescribing clinician based on the indication, patient weight, renal and hepatic function, and treatment response. Dosage regimens can vary widely, and any adjustments are made under medical supervision to balance efficacy with safety.

Methotrexate is classified as Pregnancy Category X, meaning it is contraindicated in pregnancy due to a high risk of fetal malformations and embryotoxicity. It is also not recommended while breastfeeding because it can be excreted in breast milk and may harm the infant.

To order Namaxir, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials before providing pricing, availability, shipping details (including cold‑chain where required) and import documentation.

Methotrexate is often considered a first‑line disease‑modifying antirheumatic drug (DMARD) because of its proven efficacy, oral and injectable formulations, and relatively low cost compared with biologic agents. Unlike biologics, it targets intracellular folate pathways rather than specific cytokines, offering a broad immunosuppressive effect but requiring regular laboratory monitoring.

Namaxir should be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen or shaken. Keep the product in its original packaging to maintain stability, and follow aseptic techniques when preparing for injection to avoid contamination.

Namaxir is supplied as a sterile injectable solution for epidural, intra‑articular or intramuscular injection. Administration is performed by a qualified healthcare professional using aseptic technique, with the injection site and volume determined by the prescribing clinician based on the therapeutic indication.

Serious risks include severe liver toxicity, pulmonary fibrosis, life‑threatening bone‑marrow suppression leading to pancytopenia, renal failure, and teratogenic effects. Patients should be educated to report symptoms such as persistent fatigue, unexplained bruising, shortness of breath, jaundice, or signs of infection promptly.

Methotrexate is contraindicated in pregnant women, individuals planning conception, and patients with severe renal or hepatic impairment. It should also be avoided in those with active infections, known hypersensitivity to methotrexate or its excipients, and in patients receiving live vaccines due to heightened infection risk.